RNA Therapeutics in Oncology: Advances, Challenges, and Future Directions. (October 2017)

• Record Type: Journal Article
• Authors: MacLeod, A. Robert; Crooke, Stanley T.
• Other Names: Lee Lucy guestEditor.
• Is Part Of: Journal of clinical pharmacology. Volume 57(2017)Supplement 10
• Page Start: S43
• Page End: S59
• Publication Date: 2017-10
• Subjects: RNA therapeutics -- antisense -- oligonucleotides -- RNase H1 -- microRNA (mir) -- siRNA; Pharmacology -- Periodicals; Pharmacology -- Periodicals; Pharmacology, Clinical -- Periodicals; 615.1
• DOI: 10.1002/jcph.957
• Languages: English
• ISSNs: 0091-2700

Abstract

Abstract: RNA‐based therapeutic technologies represent a rapidly expanding class of therapeutic opportunities with the power to modulate cellular biology in ways never before possible. With RNA‐targeted therapeutics, inhibitors of previously undruggable proteins, gene expression modulators, and even therapeutic proteins can be rationally designed based on sequence information alone, something that is not possible with other therapeutic modalities. The most advanced RNA therapeutic modalities are antisense oligonucleotides (ASOs) and small interfering RNAs. Particularly with ASOs, recent clinical data have demonstrated proof of mechanism and clinical benefit with these approaches across several nononcology disease areas by multiple routes of administration. In cancer, next‐generation ASOs have recently demonstrated single‐agent activity in patients with highly refractory cancers. Here we discuss advances in RNA therapeutics for the treatment of cancer and the challenges that remain to solidify these as mainstay therapeutic modalities to bridge the pharmacogenomic divide that remains in cancer drug discovery.